SepTec provides more rapid, accurate sepsis pathogen detection

Time and sensitivity of blood culture is not enough

pathogen detection
 Specimen

Specimen

Whole blood with suspected bacteria

 Microfluidic disc

Microfluidic disc

Centrifugal forces and microfluidic parameters control sample volume, flow rate and incubation time over the innovatice sensor surfaces

 Bedside Analyser

Bedside Analyser

The SepTec core technology successfully captures bacteria or fungi from whole blood as it passes over the innovative sensor surface

 YES/NO detection

YES/NO detection

SepTec rapidly detects the one YES answer that lies within a pyramid od NO answers

90% of blood cultures are negative resulting in patients frequently left on unnecessary antibiotics

antibiotics

Our Technology

Platform

This patent pending technology rapidly detects pathogens present in a suspected sepsis patient within 15 minutes without the need for blood culture or PCR amplification. The cost effective technology, that can be used by individuals without specialist training is designed from the ground up to find global application.

SepTec will allow the physician to rapidly differentiate between bacterial and fungal infections so that they can administer the appropriate therapy. Significantly, by quickly ruling out sepsis in patients with other conditions, SepTec contributes to the global goal of reducing antibiotic use and helps to stop antimicrobial resistance occurring.

Deliverables

Rapid tests (“sample-in-result-out”) that can be used by health care personnel at or close to the bedside and that provide rapid information (within 15 minutes) about the presence or absence of sepsis, the definitive species of pathogens and prevent patients without sepsis from being treated with antibiotics.

Impact of SepTec

Reduced healthcare costs

Reduced antibiotics resistance

Reduced length of hospital stay

Reduced broad spectrum antibiotics usage

Reduced mortality & morbidity

Eliminate test contamination (false positives)

As many as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.

Funding & collaborators

Funding

SepTec has been developed and is being commercialized through Enterprise Ireland's Commercialization Fund, co-funded by the European Regional Development Fund (ERDF) under Ireland's Structural and Investment 2014-2020

 Enterprise Ireland logo
 Science Foundation Ireland logo
 Dublin City University logo
 EIT logo
 EU logo
 Irelands European Structural Investment Funds Programmes logo
 MedTech Innovator Accelerator Badge logo
 Lil Red logo

Clinical collaborators

SepTec is grateful to their clinical collaborators The Coombe Women & Children's Hospital, St. James's Hospital & Beaumont Hospital, Dublin, Ireland

 Beaumont Hospital logo
 St James Hospital logo
 Coombe Hospital logo

Programmes & workshops

The SepTec team are delighted to have been given the opportunity to have participated in start-up programmes and workshops that will accelerate the team's business development, skills and contacts that are crucial towards successfully starting and growing the future SepTec company.

 New Frontiers logo
 Enterprise Start 2 logo
 Invent DCU logo
 Enterprise Start logo
 Seedcorn logo
 Startup Academy logo
 ECIU logo
 DCU RYAN logo
 MedTech Innovator Accelerator Badge logo
 EIT logo
 Startup Lighthouse logo